

Ertugliflozin / Metformin Formulation

Version 4.0 Revision Date: 04/12/2018 SDS Number: 590562-00006 Date of last issue: 12/12/2017
Date of first issue: 04/01/2016

SECTION 1. IDENTIFICATION

Product name : Ertugliflozin / Metformin Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc

Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - U.S.A. 07033

Telephone : 908-740-4000

Telefax : 908-735-1496

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with 29 CFR 1910.1200**

Combustible dust

Acute toxicity (Oral) : Category 4

GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.
H302 Harmful if swallowed.

Precautionary Statements : **Prevention:**
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
Response:
P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth.
Disposal:
P501 Dispose of contents/ container to an approved waste dis-

Ertugliflozin / Metformin Formulation

Version Revision Date: SDS Number: Date of last issue: 12/12/2017
4.0 04/12/2018 590562-00006 Date of first issue: 04/01/2016

posal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous ingredients

Chemical name	CAS-No.	Concentration (% w/w)
Metformin hydrochloride	1115-70-4	>= 70 - < 90
Cellulose	9004-34-6	>= 10 - < 20
Magnesium stearate	557-04-0	>= 1 - < 5
Ertugliflozin	1210344-83-4	>= 0.1 - < 1

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately., When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.
- In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.
- Most important symptoms and effects, both acute and delayed : Harmful if swallowed.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists.
- Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam

Ertugliflozin / Metformin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/12/2017
4.0	04/12/2018	590562-00006	Date of first issue: 04/01/2016

- Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.
- Environmental precautions : Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Ertugliflozin / Metformin Formulation

Version 4.0 Revision Date: 04/12/2018 SDS Number: 590562-00006 Date of last issue: 12/12/2017
 Date of first issue: 04/01/2016

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
 Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.
 Do not swallow.
 Avoid contact with eyes.
 Avoid prolonged or repeated contact with skin.
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
 Minimize dust generation and accumulation.
 Keep container closed when not in use.
 Keep away from heat and sources of ignition.
 Take precautionary measures against static discharges.
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
 Store in accordance with the particular national regulations.
- Materials to avoid : No special restrictions on storage with other products.

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Metformin hydrochloride	1115-70-4	TWA	2 mg/m ³ (OEB 1)	Internal
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1
Magnesium stearate	557-04-0	TWA (Inhalable fraction)	10 mg/m ³	ACGIH
		TWA (Respirable fraction)	3 mg/m ³	ACGIH
Ertugliflozin	1210344-83-4	TWA	10 µg/m ³ (OEB 3)	Internal
		Wipe limit	100 µg/100 cm ²	Internal

- Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

Ertugliflozin / Metformin Formulation

Version 4.0 Revision Date: 04/12/2018 SDS Number: 590562-00006 Date of last issue: 12/12/2017
Date of first issue: 04/01/2016

protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

- Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : Ensure that eye flushing systems and safety showers are located close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Ertugliflozin / Metformin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/12/2017
4.0	04/12/2018	590562-00006	Date of first issue: 04/01/2016

Appearance	:	powder
Color	:	No data available
Odor	:	No information available.
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

Ertugliflozin / Metformin Formulation

Version 4.0 Revision Date: 04/12/2018 SDS Number: 590562-00006 Date of last issue: 12/12/2017
Date of first issue: 04/01/2016

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : None.

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 1,337 mg/kg
Method: Calculation method

Components:**Metformin hydrochloride:**

Acute oral toxicity : LD50 (Rat): 1,000 mg/kg
LD50 (Mouse): 1,450 - 3,500 mg/kg
LD50 (Monkey): 463 mg/kg
LD50 (Rabbit): 350 mg/kg
LD50 (Guinea pig): 500 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h

Ertugliflozin / Metformin Formulation

Version 4.0 Revision Date: 04/12/2018 SDS Number: 590562-00006 Date of last issue: 12/12/2017
 Date of first issue: 04/01/2016

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
 Assessment: The substance or mixture has no acute dermal toxicity

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,500 mg/kg
 Assessment: The substance or mixture has no acute oral toxicity

Ertugliflozin:

Acute oral toxicity : LD50 (Rat): 500 mg/kg
 Acute inhalation toxicity : Remarks: No data available
 Acute dermal toxicity : Remarks: No data available

Skin corrosion/irritation

Not classified based on available information.

Components:

Metformin hydrochloride:

Species : Rabbit
 Result : Mild skin irritation

Cellulose:

Result : No skin irritation
 Remarks : Based on data from similar materials

Ertugliflozin:

Result : Corrosive

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Metformin hydrochloride:

Species : Rabbit
 Result : Mild eye irritation

Cellulose:

Result : No eye irritation
 Remarks : Based on data from similar materials

Ertugliflozin:

Result : Severe irritation

Ertugliflozin / Metformin Formulation

Version 4.0 Revision Date: 04/12/2018 SDS Number: 590562-00006 Date of last issue: 12/12/2017
 Date of first issue: 04/01/2016

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Cellulose:

Test Type	: Local lymph node assay (LLNA)
Routes of exposure	: Skin contact
Species	: Mouse
Method	: OECD Test Guideline 429
Result	: negative
Remarks	: Based on data from similar materials

Magnesium stearate:

Routes of exposure	: Skin contact
Result	: negative

Ertugliflozin:

Test Type	: Local lymph node assay (LLNA)
Result	: Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:

Metformin hydrochloride:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative
	Test Type: in vitro test Test system: mouse lymphoma cells Result: negative
Genotoxicity in vivo	: Test Type: Chromosomal aberration
	Test system: Human lymphocytes
	Result: negative
Genotoxicity in vivo	: Test Type: Micronucleus test
	Species: Mouse
	Application Route: Oral
	Result: negative

Cellulose:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative
	Remarks: Based on data from similar materials

Ertugliflozin / Metformin Formulation

Version 4.0 Revision Date: 04/12/2018 SDS Number: 590562-00006 Date of last issue: 12/12/2017
 Date of first issue: 04/01/2016

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
 Species: Mouse
 Application Route: Ingestion
 Result: negative
 Remarks: Based on data from similar materials

Ertugliflozin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Test Type: Chromosome aberration test in vitro
 Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
 Species: Rat
 Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Metformin hydrochloride:

Species : Mouse
 Exposure time : 91 weeks
 Dose : 1500 mg/kg body weight
 Result : negative

Species : Rat, male
 Application Route : Oral
 Exposure time : 104 weeks
 Dose : 900 mg/kg body weight
 Result : negative

Species : Rat, female
 Application Route : Oral
 Exposure time : 104 weeks
 LOAEL : 900 mg/kg body weight
 Result : negative
 Target Organs : Uterus (including cervix)
 Remarks : The mechanism or mode of action may not be relevant in humans.

Ertugliflozin:

Species : Mouse
 Application Route : Oral
 Exposure time : 2 Years
 Result : negative

Species : Rat
 Application Route : Oral

Ertugliflozin / Metformin Formulation

Version 4.0 Revision Date: 04/12/2018 SDS Number: 590562-00006 Date of last issue: 12/12/2017
 Date of first issue: 04/01/2016

Exposure time : 2 Years
 Result : negative

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

Metformin hydrochloride:

Effects on fertility : Test Type: Fertility
 Species: Rat
 Application Route: Oral
 Fertility: NOAEL: 600 mg/kg body weight
 Result: No effects on fertility.

Effects on fetal development : Test Type: Development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: NOAEL: 600 mg/kg body weight
 Result: No teratogenic effects.

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Oral
 Embryo-fetal toxicity.: NOAEL: 140 mg/kg body weight
 Result: No teratogenic effects.

Ertugliflozin:

Effects on fertility : Test Type: Fertility/early embryonic development
 Species: Rat
 Application Route: Oral
 Fertility: NOAEL: 250 mg/kg body weight
 Remarks: Maternal toxicity observed.
 No significant adverse effects were reported

Test Type: Fertility/early embryonic development
 Species: Rabbit
 Application Route: Oral
 Fertility: NOAEL: 200 mg/kg body weight
 Remarks: No significant adverse effects were reported

Effects on fetal development : Test Type: Embryo-fetal development

Ertugliflozin / Metformin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/12/2017
4.0	04/12/2018	590562-00006	Date of first issue: 04/01/2016

Species: Rat
 Application Route: Oral
 Developmental Toxicity: NOAEL: 50 mg/kg body weight
 Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Oral
 Developmental Toxicity: NOAEL: 250 mg/kg body weight
 Remarks: No significant adverse effects were reported

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Components:

Ertugliflozin:

Routes of exposure : Oral
 Target Organs : Kidney, Stomach, Prostate
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Metformin hydrochloride:

Species : Rat
 NOAEL : 125 mg/kg
 Application Route : Oral
 Exposure time : 1 year
 Remarks : No significant adverse effects were reported

Species : Rabbit
 NOAEL : 100 mg/kg
 Application Route : Oral
 Exposure time : 1 Year
 Remarks : No significant adverse effects were reported

Species : Dog
 NOAEL : 50 mg/kg
 Application Route : Subcutaneous
 Exposure time : 2 year
 Remarks : No significant adverse effects were reported

Cellulose:

Species : Rat
 NOAEL : > 5,000 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days
 Remarks : Based on data from similar materials

Ertugliflozin / Metformin Formulation

Version 4.0 Revision Date: 04/12/2018 SDS Number: 590562-00006 Date of last issue: 12/12/2017
Date of first issue: 04/01/2016

Magnesium stearate:

Species : Rat
NOAEL : 5,000 mg/kg
Application Route : Ingestion
Exposure time : 3 Months

Ertugliflozin:

Species : Rat
LOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 30 d

Species : Rat
LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 30 d
Target Organs : Kidney

Species : Rat
LOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 180 d
Target Organs : Kidney, Bone, Stomach

Species : Rat
LOAEL : 25 mg/kg
Exposure time : 90 d
Target Organs : Kidney, Gastrointestinal tract, Prostate

Species : Dog
NOAEL : 150 mg/kg
Application Route : Oral
Exposure time : 270 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 28 d
Target Organs : Bone
Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Ertugliflozin / Metformin Formulation

Version 4.0 Revision Date: 04/12/2018 SDS Number: 590562-00006 Date of last issue: 12/12/2017
 Date of first issue: 04/01/2016

Experience with human exposure

Components:

Metformin hydrochloride:

Skin contact : Remarks: May irritate skin.
 Eye contact : Remarks: May irritate eyes.
 Ingestion : Symptoms: Diarrhea, Nausea, Vomiting, Gastrointestinal discomfort, flatulence, asthenia, Fatigue, Headache

Ertugliflozin:

Ingestion : Symptoms: The most common side effects are:, Headache, constipation, Diarrhea, Nausea, urinary tract infection, muscle pain, upper respiratory tract infection

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Metformin hydrochloride:

Toxicity to algae : EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
 Method: OECD Test Guideline 201
 NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
 Method: OECD Test Guideline 201
 Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 10 mg/l
 Exposure time: 33 d
 Method: OECD Test Guideline 210
 Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 40 mg/l
 Exposure time: 21 d
 Method: OECD Test Guideline 211
 Toxicity to microorganisms : EC50: > 1,000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition
 Method: OECD Test Guideline 209

Cellulose:

Toxicity to fish : LC50 (Cyprinus carpio (Carp)): > 100 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203
 Remarks: Based on data from similar materials
 Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
 Exposure time: 48 h

Ertugliflozin / Metformin Formulation

Version 4.0 Revision Date: 04/12/2018 SDS Number: 590562-00006 Date of last issue: 12/12/2017
 Date of first issue: 04/01/2016

Method: OECD Test Guideline 202
 Remarks: Based on data from similar materials

Toxicity to algae : EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201
 Remarks: Based on data from similar materials

Ertugliflozin:

Toxicity to algae : EC50 (Pseudokirchneriella subcapitata (green algae)): 77 mg/l
 Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 50 mg/l
 Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 1 mg/l
 Exposure time: 32 d
 Method: OECD Test Guideline 210
 Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 2.14 mg/l
 Exposure time: 21 d
 Method: OECD Test Guideline 211
 Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 1,000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition
 Method: OECD Test Guideline 209

NOEC: 1,000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition
 Method: OECD Test Guideline 209

Persistence and degradability

Components:

Metformin hydrochloride:

Biodegradability : Result: rapidly degradable
 Biodegradation: 50 %
 Exposure time: 2 hrs

Cellulose:

Biodegradability : Result: Readily biodegradable.

Magnesium stearate:

Biodegradability : Result: Not biodegradable.

Ertugliflozin / Metformin Formulation

Version 4.0 Revision Date: 04/12/2018 SDS Number: 590562-00006 Date of last issue: 12/12/2017
Date of first issue: 04/01/2016

Ertugliflozin:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 40.8 %
Exposure time: 28 d

Bioaccumulative potential**Components:****Metformin hydrochloride:**

Partition coefficient: n-octanol/water : log Pow: -2

Ertugliflozin:

Partition coefficient: n-octanol/water : log Pow: 2.47

Mobility in soil**Components:****Metformin hydrochloride:**

Distribution among environmental compartments : log Koc: 4.3
Method: OECD Test Guideline 106

Ertugliflozin:

Distribution among environmental compartments : log Koc: 2.88

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

Ertugliflozin / Metformin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/12/2017
4.0	04/12/2018	590562-00006	Date of first issue: 04/01/2016

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust
Acute toxicity (any route of exposure)

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Metformin hydrochloride	1115-70-4
Cellulose	9004-34-6
Polyvinyl pyrrolidone	9003-39-8

California Prop. 65

This product does not contain any chemicals known to the State of California to cause cancer, birth, or any other reproductive defects.

California List of Hazardous Substances

Polyvinyl pyrrolidone	9003-39-8
-----------------------	-----------

California Permissible Exposure Limits for Chemical Contaminants

Cellulose	9004-34-6
Magnesium stearate	557-04-0

The ingredients of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined


Ertugliflozin / Metformin Formulation

Version 4.0 Revision Date: 04/12/2018 SDS Number: 590562-00006 Date of last issue: 12/12/2017
 Date of first issue: 04/01/2016

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



HMIS® IV:

HEALTH	/	1
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	:	8-hour time weighted average

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of

Ertugliflozin / Metformin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/12/2017
4.0	04/12/2018	590562-00006	Date of first issue: 04/01/2016

Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 04/12/2018

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8